Title
Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2.

Permalink
https://escholarship.org/uc/item/9kp7b9qv

Journal
The Journal of experimental medicine, 192(7)

ISSN
0022-1007

Authors
Izikson, L
Klein, RS
Charo, IF
et al.

Publication Date
2000-10-01

DOI
10.1084/jem.192.7.1075

Peer reviewed
Resistance to Experimental Autoimmune Encephalomyelitis in Mice Lacking the CC Chemokine Receptor (CCR2)

By Leonid Izikson,* Robyn S. Klein,‡ Israel F. Charo,§ Howard L. Weiner,* and Andrew D. Luster‡

From the *Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115; the ‡Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114; and the §Gladstone Institute, University of California at San Francisco, San Francisco, California 94141

Abstract
Monocyte recruitment to the central nervous system (CNS) is a necessary step in the development of pathologic inflammatory lesions in experimental autoimmune encephalomyelitis (EAE), a murine model of multiple sclerosis. Monocyte chemoattractant protein (MCP)-1, a potent agonist for directed monocyte migration, has been implicated in the pathogenesis of EAE. Here we report that deficiency in CC chemokine receptor (CCR)2, the receptor for MCP-1, confers resistance to EAE induced with a peptide derived from myelin oligodendrocyte glycoprotein peptide 35–55 (MOGp35–55). CCR2−/− mice immunized with MOGp35–55 failed to develop mononuclear cell inflammatory infiltrates in the CNS and failed to increase CNS levels of the chemokines RANTES (regulated on activation, normal T cell expressed and secreted), MCP-1, and interferon (IFN)-inducible protein 10 (IP-10) as well as the chemokine receptors CCR1, CCR2, and CCR5. Additionally, T cells from CCR2−/− immunized mice showed decreased antigen-induced proliferation and production of IFN-γ compared with wild-type immunized controls, suggesting that CCR2 enhances the T helper cell type 1 immune response in EAE. These data indicate that CCR2 plays a necessary and nonredundant role in the pathogenesis of EAE.

Key words: receptors, chemokine • chemokines • macrophages • encephalomyelitis • cytokines

Introduction
Chemokines are chemotactic cytokines that share important structural features and the ability to attract leukocytes. The regulated interactions of chemokines with their respective cell surface receptors mediate the recruitment of specific leukocyte subpopulations to sites of inflammation. The two major families of chemokines are distinguished by whether the first two of the four cysteine residues are separated by one amino acid (CXC, α-chemokines) or occur adjacent to each other (CC, β-chemokines). Whereas CXC chemokines are chemotactic mainly for neutrophils and lymphocytes, CC chemokines preferentially attract monocytes, eosinophils, basophils, and lymphocytes with variable selectivity. The CC chemokine family includes the monocyte chemoattractant protein (MCP)–eotaxin subfamily, containing MCP-1, -2, -3, -4, and -5 as well as eotaxin, all of which share ~60% identity (1).

MCP-1 is a potent in vivo monocyte chemoattractant secreted by a variety of cell types in response to proinflammatory stimuli (2). Chemotactic and activating functions of MCP-1 are directed at monocytes, activated T cells, NK cells, and basophils. MCP-1 binds solely to CC chemokine receptor (CCR)2, a seven-transmembrane–spanning protein that is functionally linked to downstream signaling pathways through heterotrimeric G proteins (3). CCR2 is expressed on peripheral blood monocytes and activated T cells (4) and serves as the receptor for five ligands, MCP-1, -2, -3, -4, and -5 (3).

MCP-1 and CCR2 have been implicated in a number of inflammatory diseases, including multiple sclerosis (MS; references 5–7), a chronic inflammatory disease of the central nervous system (CNS), and experimental autoimmune encephalomyelitis (EAE), the animal model for MS (8–13). EAE is mediated by activated neuroantigen-specific CD4+ T cells, containing MCP-1, -2, -3, -4, and -5 as well as eotaxin, all of which share ~60% identity (1).

MCP-1 is a potent in vivo monocyte chemoattractant secreted by a variety of cell types in response to proinflammatory stimuli (2). Chemotactic and activating functions of MCP-1 are directed at monocytes, activated T cells, NK cells, and basophils. MCP-1 binds solely to CC chemokine receptor (CCR)2, a seven-transmembrane–spanning protein that is functionally linked to downstream signaling pathways through heterotrimeric G proteins (3). CCR2 is expressed on peripheral blood monocytes and activated T cells (4) and serves as the receptor for five ligands, MCP-1, -2, -3, -4, and -5 (3).

MCP-1 and CCR2 have been implicated in a number of inflammatory diseases, including multiple sclerosis (MS; references 5–7), a chronic inflammatory disease of the central nervous system (CNS), and experimental autoimmune encephalomyelitis (EAE), the animal model for MS (8–13). EAE is mediated by activated neuroantigen-specific CD4+ T cells, containing MCP-1, -2, -3, -4, and -5 as well as eotaxin, all of which share ~60% identity (1).
Th1 cells and is characterized histologically by mononuclear cell infiltrates consisting of monocytes and Ag-specific and nonspecific CD4+ and CD8+ T cells (14). Monocyte recruitment to the CNS is a necessary step for the development of inflammatory lesions in EAE (15), and MCP-1 mRNA is upregulated during the acute phase of disease induced by immunization with myelin oligodendrocyte glycoprotein peptide 35–55 (MOGp35–55) or other encephalitogenic Ags (9, 10). Vaccination of mice with a naked MCP-1 DNA, resulting in anti–MCP-1 Abs, inhibited the generation EAE (16). In addition, CCR2 signaling appears to promote Th1 immune responses in vivo (17–19). Taken together, these data indicate that MCP-1 and CCR2 might play an important role in the initiation and progression of EAE.

To test the hypothesis that CCR2 signaling is required for the pathogenesis of EAE, we induced disease in CCR2−/− and CCR2+/+ animals with the encephalitogenic peptide MOGp35–55. We found that mice lacking CCR2 are resistant to EAE, fail to develop mononuclear cell infiltrates, and display decreased Ag-specific proinflammatory responses in the secondary lymphoid organs. These results suggest an essential nonredundant in vivo function for CCR2 in the pathogenesis of EAE.

Materials and Methods

Mice and EAE Induction. CCR2−/− mice were generated by homologous recombination as previously described (17). CCR2−/− and CCR2+/+ (WT) littermate controls were generated from matings between heterozygous (CCR2+/−) mice (50/50 Sv129 × C57BL/6) and raised in identical specific pathogen-free conditions. To induce EAE, CCR2−/− and WT littermates between 12 and 16 wk of age were immunized in the footpad with a total of 100 μg of MOGp35–55 (MGH Peptide Synthesis Facility, Charlestown, MA) emulsified in CFA (Difco Labs.); mice also received two intraperitoneal injections of 200 ng of Pertussis toxin (List Biological Laboratories) on days 0 and 2 after immunization. Animals were scored for signs of EAE using the following criteria: 1, tail paralysis; 2, hind limb weakness; 3, hindlimb paralysis; 4, hind limb plus forelimb paralysis; 5, moribund or dead.

Cytokine Production and Proliferation. Spleens from mice in each group were collected on days 8, 11, 15, 20, 23, and 26 after disease induction; popliteal LNs draining the immunization site were collected on days 8, 11, 15, 20, 23, and 26 after disease induction and fixed in 10% formalin in PBS. Brains and spinal cords from mice in each group were collected on days 8, 11, 15, 20, 23, and 26 after disease induction; popliteal LNs draining the immunization site were collected on days 8, 11, 15, 20, 23, and 26 after disease induction and fixed in 10% formalin in PBS. Brains and spinal cords from mice in each group were collected on days 8, 11, 15, 20, 23, and 26 after disease induction; popliteal LNs draining the immunization site were collected on days 8, 11, 15, 20, 23, and 26 after disease induction and fixed in 10% formalin in PBS. Perinatal mice were generated by homologous recombination as previously described (17).

CNS Histology. Brains and spinal cords from mice in each group were collected on days 8, 11, 15, 20, 23, and 26 after disease induction and fixed in 10% formalin in PBS. Paraffin-embedded tissues were sectioned 5 μm thick at 60-μm intervals and stained with hematoxylin and eosin as well as the myelin-specific stain Luxol fast blue. Slides were analyzed in a blinded fashion for lesion activity and type of infiltrating cells.

Results and Discussion

CCR2−/− Mice Are Resistant to Induction of EAE. To test the contribution of CCR2 signaling in the initiation and progression of EAE, CCR2−/− and CCR2+/+ mice were immunized with the encephalitogenic peptide MOGp35–55 and scored for signs of disease (Fig. 1). MOGp35–55 is an effective encephalitogen in the suscepti-
ble strain C57/BL6 bearing the H-2b MHC haplotype (20). As mice used in these experiments were littersmates generated by crossing C57BL6/Sv129 parents heterozygous at the CCR2 locus, the offspring expressed H-2b and would be expected to remain susceptible to MOGp35–55-induced EAE. As expected, wild-type offspring developed clinical EAE, with a mode incidence of 80%. In contrast, their CCR2-deficient littersmates completely failed to express signs of clinical disease in 24 of 26 CCR2-deficient mice analyzed. The two CCR2-deficient mice that developed disease had significantly delayed onset and decreased maximal disease severity compared with the wild-type littersmates (data not shown).

_Paucity of Inflammatory Lesions in CCR2<sup>−/−</sup> Mice Immunized with MOGp35–55._ To explore the basis of resistance to disease in CCR2-deficient mice, we examined the CNS tissues from mice in both groups. On histological examination (n = 6 mice per group), there were numerous meningeal and CNS parenchymal inflammatory/demyelinating lesions exclusively in the wild-type mice that also showed signs of clinical EAE (Fig. 2). These lesions consisted mainly of lymphocytic and monocytic infiltrates with few granulocytes. There were also varying degrees of optic and perioptic neuritis (data not shown). In contrast, CCR2-deficient littersmates failed to develop CNS inflammation, which correlated with the absence of clinical EAE in these mice (Fig. 2).

**CNS Chemokine and Chemokine Receptor Expression Is Not Detected in Immunized CCR2<sup>−/−</sup> Mice.** To address the mechanism underlying the inability of CCR2<sup>−/−</sup> mice to produce active lesions, we examined the CNS chemokine profile from CCR2<sup>−/−</sup> and CCR2<sup>+/+</sup> mice during the development of EAE. RNase Protection assays performed on brains from wild-type mice immunized with MOG35–55 revealed the upregulation of CCR2<sup>−/−</sup> and CCR2<sup>+/+</sup> mice during the development of EAE. RNase Protection assays performed on brains from wild-type mice immunized with MOG35–55 revealed the upregulation of CCR2<sup>−/−</sup> and CCR2<sup>+/+</sup> mice during the development of EAE. RNase Protection assays performed on brains from wild-type mice immunized with MOG35–55 revealed the upregulation of CCR2<sup>−/−</sup> and CCR2<sup>+/+</sup> mice during the development of EAE.

We also examined the phenotype of MOGp35–55-specific T cells found in the spleen at different points in the disease course. As CCR2-deficient mice are resistant to developing inflammatory lesions and clinical signs of EAE, we analyzed the phenotype of T cells generated by immunization with MOGp35–55 in CCR2-deficient and wild-type mice (Fig. 4). Draining LN cells from wild-type mice showed robust proliferative responses to Ag, with stimulation indices approximately two times higher than in LN cells from the CCR2-deficient animals (Fig. 4). IFN-γ, a proinflammatory Th1 cytokine known to be involved in the pathogenesis of EAE, was also decreased in CCR2-deficient mice compared with wild-type mice (Fig. 4). Both groups secreted similar levels of IL-6 (Fig. 4).

Figure 2. Histology of CNS tissue from MOGp35–55-immunized mice. Hematoxylin and eosin-stained, formalin-fixed cerebellum (A and B) and spinal cord (C and D) from CCR2<sup>+/+</sup> (A and C) and CCR2<sup>−/−</sup> mice (B and D) after immunization with MOG35–55. Representative (n = 6 mice per group) perivascular inflammatory lesions (indicated by arrows) composed of mononuclear cells are shown in CCR2<sup>−/−</sup> brain and spinal cord sections. Note the absence of lesions and inflammatory cells in the sections from the brain and spinal cord of CCR2<sup>−/−</sup> mice. Original magnification 240X.
course of disease. At days 8, 11, 20, 23, and 26 after disease induction, splenocytes from CCR2-deficient mice also proliferated less robustly to Ag and secreted lower levels of IFN-γ and IL-6 than splenocytes from wild-type controls, paralleling the finding of decreased Th1 expression in draining LNs. In contrast, when cells were stimulated with nonspecific stimuli such as Con A or the anti-CD3 mAb, splenocytes from CCR2-deficient mice showed proliferation that was equal to that of cells from wild-type littermates (data not shown). This suggests that the decreased effector responses were Ag specific and did not result from a generalized defect in T cell activation or function. Taken together, these observations indicate that resistance to EAE in CCR2-deficient mice is associated with a decreased Ag-specific Th1 effector response.

As T cell differentiation and activation in vivo involves effective Ag presentation, we also tested whether the observed differences in Ag-specific T cell responses in vitro could result from impaired Ag presentation in the LN. Dendritic cells are potent immunostimulatory cells found in the T cell areas of the LN. Recent studies concerning the origin of these cells suggest that monocytes recruited to an inflammatory focus acquire Ag by phagocytosis and then rapidly leave the tissue as they migrate into the LN and differentiate into dendritic cells (21). Therefore, we asked whether deficiency in CCR2, a key monocyte chemoattractant receptor, impairs the accumulation of phagocytes in the LN. In preliminary experiments, we found that CCR2^{−/−} mice did not show decreased phagocyte migration to the LN 10 d after they were immunized with fluorescent beads in CFA (data not shown). This indicates that monocyte recruitment to the site of immunization and the LN are not overtly impaired in the CCR2^{−/−} mice and most likely do not account for the observed decreased T cell responses.

Our observations provide functional evidence that CCR2 signaling is essential in the inflammatory cascade that culminates in clinical disease. These findings suggest that MCP-1 or other CCR2 agonists, induced in the CNS
by activated neuroantigen-specific T cells, are necessary for the recruitment of peripheral blood monocytes into the brain and spinal cord. These monocytes serve to amplify the initial local T cell–mediated response in the CNS into an active lesion where macrophages become sufficiently numerous and activated to digest the myelin sheath, leading to demyelination, axonal dysfunction, and clinical manifestations of disease. Our results implicating CCR2 as an important receptor mediating monocyte recruitment in vivo are consistent with similar findings in other inflammatory disease models characterized by macrophage tissue accumulation (17, 19, 22–24).

In addition, our data suggests that CCR2 signaling enhances Ag-specific effector Th1 responses in vivo. Previous in vivo studies have also found decreased Th1 immune responses in CCR2−/− mice (17–19), although the mechanism for this observation has not been completely elucidated. MCP-1 has been shown to directly costimulate T cell activation in vitro, suggesting that CCR2 signaling may directly augment T cell proliferation and cytokine secretion (25, 26). Our data further the notion that CCR2 signaling plays a role in Th1 immune responses in vivo.

In summary, we demonstrate that CCR2 is required for the pathogenesis of an organ-specific T cell and macrophage-mediated inflammatory disease, EAE, a model of MS. Accordingly, the existence of MCP-1 and CCR2 gene mutations in the human population may be important determinants in the initiation and/or progression of autoimmune diseases, and CCR2 antagonism might represent a potential therapeutic approach for such conditions.

We would like to thank Ray Sobel for expert analysis of histopathology and Anthony Slavin for help with this work.

This work was supported by National Institutes of Health grants KO8-DA00522 (to R.S. Klein), R01-AI43458 (to H.L. Weiner), and RO1-CA69212 and RO1-AI4699 (to A.D. Luster) and a Charles E. Culpeper Medical Scientist Award to A.D. Luster.

Submitted: 5 July 2000
Accepted: 31 July 2000

References

1. Luster, A.D. 1998. Chemokines: chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 388:436–445.
2. Gu, L., S.C. Tseng, and B.J. Rollins. 1999. Monocyte chemoattractant protein-1. Chem. Immunol. 72:7–29.
3. Charo, I.F. 1999. CCR2: from cloning to the creation of knockout mice. Chem. Immunol. 72:30–41.
4. Frade, J.M., M. Mellado, G. del Real, J.C. Gutierrez-Ramos, P. Lind, and A.C. Martinez. 1997. Characterization of the CCR2 chemokine receptor: functional CCR2 receptor expression in B cells. J. Immunol. 159:5576–5584.
5. Simpson, J.E., J. Newcombe, M.L. Cuzner, and M.N. Woodroofe. 1998. Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J. Neuroimmunol. 84:238–249.
6. Van Der Voorn, P., J. Tekstra, R.H. Beelen, C.P. Tensen, P. Van Der Valk, and C.J. De Groot. 1999. Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions. Am. J. Pathol. 154:45–51.
7. Balashov, K., J. Rottman, H. Weiner, and W. Hancock. 1999. CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1 and IP-10 are expressed in demyelinating brain lesions. Proc. Natl. Acad. Sci. USA. 96:6873–6878.
8. Hulker, K., C.F. Brosnan, D.A. Aquino, W. Cammer, S. Kulkshrestha, M.P. Guida, D.A. Rapoport, and J.W. Berman. 1993. Expression of CSF-1, c-fms, and MCP-1 in the central nervous system of rats with experimental allergic encephalomyelitis. J. Immunol. 150:2525–2533.
9. Kennedy, K.J., R.M. Strieter, S.L. Kunkel, N.W. Lukacs, and W.J. Karpus. 1998. Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1 alpha and monocyte chemotactic protein-1. J. Neuroimmunol. 92:98–108.
10. Juedes, A.E., P. Hjelmstrom, C.M. Bergman, A.L. Neild, and N.H. Ruddle. 2000. Kinetics and cellular origin of cytokines in the central nervous system: insight into mechanisms of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis. J. Immunol. 164:419–426.
11. Godiska, R., D. Chantry, G.N. Dietsch, and P.W. Gray. 1995. Chemokine expression in murine experimental allergic encephalomyelitis. J. Neuroimmunol. 58:167–176.
12. Glabinski, A.R., M. Tani, R.M. Strieter, V.K. Tuohy, and R.M. Ransohoff. 1997. Synchronous synthesis of alpha- and beta-chemokines by cells of diverse lineage in the central nervous system of mice with relapses of chronic experimental autoimmune encephalomyelitis. Am. J. Pathol. 150:617–630.
13. Jiang, Y., M.N. Salafranca, S. Adhkari, Y. Xia, L. Feng, M.K. Sonntag, C.M. deFiebre, N.A. Pennell, W.J. Streit, and J.K. Harrison. 1998. Chemokine receptor expression in cultured glia and rat experimental allergic encephalomyelitis. J. Neuroimmunol. 86:1–12.
14. Karpus, W.J., and R.M. Ransohoff. 1998. Chemokine regulation of experimental autoimmune encephalomyelitis: temporal and spatial expression patterns govern disease pathogenesis. J. Immunol. 161:2667–2671.
15. Tran, E.H., K. Hoekstra, N. van Rooijen, C.D. Dijkstra, and T. Owens. 1998. Immune invasion of the central nervous system parenchyma and experimental allergic encephalomyelitis, but not leukocyte extravasation from blood, are prevented in macrophage-depleted mice. J. Immunol. 161:3767–3775.
16. Youssef, S., G. Wildbaum, G. Maor, N. Lanir, A. Gour-Lavie, N. Grabie, and N. Karin. 1998. Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines. J. Immunol. 161:3870–3879.
17. Boring, L., J. Gosling, S. Chensue, S. Kunkel, R.J. Fares, H. Brockmeyer, and I. Charo. 1997. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J. Clin. Invest. 100:2552–2561.
18. Warmington, K.S., L. Boring, J.H. Ruth, J. Sonstein, C.M. Hogaboam, J.L. Curtis, S.L. Kunkel, I.R. Charo, and S.W. Chensue. 1999. Effect of C-C chemokine receptor 2 (CCR2) knockout on type-2 (schistosomal antigen–elicited) pulmonary granuloma formation: analysis of cellular recruitment and cytokine responses. Am. J. Pathol. 154:1407–1416.
19. Traynor, T.R., W.A. Kuziel, G.B. Toews, and G.B. Huffergle. 2000. CCR2 expression determines T1 versus T2 polarization during pulmonary Cryptococcus neoformans infection. J. Immunol. 164:2021–2027.

20. Wekerle, H., K. Kojima, J. Lannes-Vieira, H. Lassmann, and C. Linington. 1994. Animal models. Ann. Neurol. 36:S47–53.

21. Randolph, G.J., K. Inaba, D.F. Robbani, R.M. Steinman, and W.A. Muller. 1999. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity. 11:753–761.

22. Kurihara, T., G. Warr, J. Loy, and R. Bravo. 1997. Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. J. Exp. Med. 186:1757–1762.

23. Kuziel, W.A., S.J. Morgan, T.C. Dawson, S. Griffin, O. Smithies, K. Ley, and N. Maeda. 1997. Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. Proc. Natl. Acad. Sci. USA. 94:12053–12058.

24. Boring, L., J. Gosling, M. Cleary, and I.F. Charo. 1998. Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 394:894–897.

25. Taub, D.D., S.M. Turcovski-Corrales, M.L. Key, D.L. Longo, and W.J. Murphy. 1996. Chemokines and T lymphocyte activation: I. Beta chemokines costimulate human T lymphocyte activation in vitro. J. Immunol. 156:2095–2103.

26. Taub, D.D., J.R. Ortaldo, S.M. Turcovski-Corrales, M.L. Key, D.L. Longo, and W.J. Murphy. 1996. Beta chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production. J. Leukoc. Biol. 59:81–89.